PrimaryMarkets welcomes you to the Imugene Investor Centre. We are actively supporting awareness and promotion of this ASX-listed biopharmaceutical company.
The Imugene Board of Directors have directed PrimaryMarkets to introduce Imugene to all those interested.
Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing various cancer immunotherapies. Their mission is to build
a pipeline of B-cell peptide cancer vaccines and therapeutics with lead products such as – HER-Vaxx – a proprietary therapeutic cancer immunotherapy
that stimulates a polyclonal antibody response. Imugene is also developing a B cell vaccine, KEY-Vaxx.
To view the Imugene share price, announcements, presentation/reports, commentary note, news and videos, please use the Imugene navigation bar on
the side panel.
.png)
BlackWall
Blooms the Chemist
Haoma Mining
Moneytech
Pelathon
Planet Group Holdings
PrimaryMarkets
VGW Holdings
XYZ Ltd
Genex Power
Capital Raises
Secondary Trading
